

Correction: Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis

Shufang Fu^{1,*}, Xin Wen^{2,*}, Fei Han³, Yin Long⁴ and Gaosi Xu¹

¹ Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, China

² Grade 2013, School of Stomatology, Nanchang University, Nanchang, China

³ Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

⁴ Grade 2013, The Second Clinical Medical College of Nanchang University, Nanchang, China

* Co-first authors contributed equally to this work

Published: January 15, 2018

Copyright: Fu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Dr. Fu and Dr. Xu citations have been changed to affiliation 1 and affiliation 5 is now deleted.

Original article: Oncotarget. 2017; 8:89364-89374. <https://doi.org/10.18632/oncotarget.19382>